Myeloperoxidase, osteopontin and asymmetrical dimethylarginine as biomarkers of pulmonary hypertension severity

Kazimli, A.; Ryzhkov, Anton; Гончарова, Н. С.; Naymushin, A. V.; Моисеева, О. М.

doi:10.1093/eurheartj/eht307.p332

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated MPO concentration and activity are associated with many pathological factors that lead to the onset and progression of inflammatory events. Recent studies have shown that MPO can serve as an important diagnostic biomarker and therapeutic target. , Therefore, screening for active compounds that can effectively inhibit MPO activity and thus attenuate the inflammatory response is the focus of current research. ,, To evaluate the potential of biosensors in screening for MPO inhibitors, we used 4-aminobenzoic acid hydrazide (4-ABAH), a drug widely used as an irreversible inhibitor of MPO, as a model. As shown in Figure g, the F A / F D ratio decreased with the increasing concentration of 4-ABAH (0–15 μM).…”

mentioning

confidence: 99%

Oxidative Cleavage-Based Three-Dimensional DNA Biosensor for Ratiometric Detection of Hypochlorous Acid and Myeloperoxidase

Wang

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

Methods to detect and quantify disease biomarkers with high specificity and sensitivity in biological fluids play a key role in enabling clinical diagnosis, including point-of-care testing. Myeloperoxidase (MPO) is an emerging biomarker for the detection of inflammation, neurodegenerative diseases, and cardiovascular disease, where excess MPO can lead to oxidative damage to biomolecules in homeostatic systems. While numerous methods have been developed for MPO analysis, most techniques are challenging in clinical applications due to the lack of amplification methods, high cost, or other practical drawbacks. Enzyme-linked immunosorbent assays are currently used for the quantification of MPO in clinical practice, which is often limited by the availability of antibodies with high affinity and specificity and the significant nonspecific binding of antibodies to the analytical surface. In contrast, nucleic acid-based biosensors are of interest because of their simplicity, fast response time, low cost, high sensitivity, and low background signal, but detection targets are limited to nucleic acids and non-nucleic acid biomarkers are rare. Recent studies reveal that the modification of a genome in the form of phosphorothioate is specifically sensitive to the oxidative effects of the MPO/H 2 O 2 /Cl − system. We developed an oxidative cleavage-based threedimensional DNA biosensor for rapid, ratiometric detection of HOCl and MPO in a "one-pot" method, which is simple, stable, sensitive, specific, and time-saving and does not require a complex reaction process, such as PCR and enzyme involvement. The constructed biosensor has also been successfully used for MPO detection in complex samples. This strategy is therefore of great value in disease diagnosis and biomedical research.

show abstract

mentioning

confidence: 99%

Oxidative Cleavage-Based Three-Dimensional DNA Biosensor for Ratiometric Detection of Hypochlorous Acid and Myeloperoxidase

Wang

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…In a parallel comparison study, it was found that the levels of circulating osteopontin in PH patients increased to a similar extent as they did in patients with DCM and left ventricular hypertrophy compared to healthy controls [47]. Several studies demonstrated a correlation of circulating osteopontin levels with a number of hemodynamic parameters such as mPAP [42], pulmonary artery dispensability index [50], right atrial pressure [51], cardiac index [42], and total pulmonary vascular resistance [42] in PH patients. Similarly, correlation of osteopontin levels with pulmonary hemodynamics and several RV remodeling parameters was demonstrated in patients with DCM [49].…”

Section: Osteopontin As a Biomarker Of Pulmonary Hypertension And Rig...mentioning

confidence: 73%

“…An increase in circulating osteopontin was associated with development of Eisenmenger syndrome in CHD-PAH patients [42]. In PAH patients, baseline circulating osteopontin levels predicted survival [51][52][53] and increased with worsening of the disease condition as assessed by six-minute walking distance (6MWD) [50,51] and New York Heart Association Functional Classification (NYHA-FC) [51,52].…”

Section: Osteopontin As a Biomarker Of Pulmonary Hypertension And Rig...mentioning

confidence: 99%

Osteopontin in Pulmonary Hypertension

et al. 2023

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a pathological condition with multifactorial etiology, which is characterized by elevated pulmonary arterial pressure and pulmonary vascular remodeling. The underlying pathogenetic mechanisms remain poorly understood. Accumulating clinical evidence suggests that circulating osteopontin may serve as a biomarker of PH progression, severity, and prognosis, as well as an indicator of maladaptive right ventricular remodeling and dysfunction. Moreover, preclinical studies in rodent models have implicated osteopontin in PH pathogenesis. Osteopontin modulates a plethora of cellular processes within the pulmonary vasculature, including cell proliferation, migration, apoptosis, extracellular matrix synthesis, and inflammation via binding to various receptors such as integrins and CD44. In this article, we provide a comprehensive overview of the current understanding of osteopontin regulation and its impact on pulmonary vascular remodeling, as well as consider research issues required for the development of therapeutics targeting osteopontin as a potential strategy for the management of PH.

show abstract

“…Several studies demonstrated elevated circulating osteopontin levels in PH patients with right HF [ 171 , 172 ]. In these patients, osteopontin levels correlated with a number of hemodynamic parameters such as pulmonary artery dispensability index [ 171 ], right atrial pressure [ 172 ], as well as functional parameters such as six-minute walking distance [ 171 , 172 ] and NYHA FC [ 172 , 173 ]. Importantly, baseline osteopontin levels were predictive of survival in PH patients [ 172 , 173 , 174 ].…”

Section: Osteopontin In Heart Failurementioning

confidence: 99%

“…Importantly, baseline osteopontin levels were predictive of survival in PH patients [ 172 , 173 , 174 ]. In addition, circulating osteopontin levels were associated with maladaptive right HF in PH patients [ 171 , 175 , 176 ].…”

Section: Osteopontin In Heart Failurementioning

confidence: 99%

Clinical and Molecular Implications of Osteopontin in Heart Failure

Mamazhakypov

Sartmyrzaeva

Sarybaev

et al. 2022

CIMB

View full text Add to dashboard Cite

The matricellular protein osteopontin modulates cell–matrix interactions during tissue injury and healing. A complex multidomain structure of osteopontin enables it not only to bind diverse cell receptors but also to interact with various partners, including other extracellular matrix proteins, cytokines, and growth factors. Numerous studies have implicated osteopontin in the development and progression of myocardial remodeling in diverse cardiac diseases. Osteopontin influences myocardial remodeling by regulating extracellular matrix production, the activity of matrix metalloproteinases and various growth factors, inflammatory cell recruitment, myofibroblast differentiation, cardiomyocyte apoptosis, and myocardial vascularization. The exploitation of osteopontin loss- and gain-of-function approaches in rodent models provided an opportunity for assessment of the cell- and disease-specific contribution of osteopontin to myocardial remodeling. In this review, we summarize the recent knowledge on osteopontin regulation and its impact on various cardiac diseases, as well as delineate complex disease- and cell-specific roles of osteopontin in cardiac pathologies. We also discuss the current progress of therapeutics targeting osteopontin that may facilitate the development of a novel strategy for heart failure treatment.

show abstract

Myeloperoxidase, osteopontin and asymmetrical dimethylarginine as biomarkers of pulmonary hypertension severity

Cited by 3 publications

References 0 publications

Oxidative Cleavage-Based Three-Dimensional DNA Biosensor for Ratiometric Detection of Hypochlorous Acid and Myeloperoxidase

Oxidative Cleavage-Based Three-Dimensional DNA Biosensor for Ratiometric Detection of Hypochlorous Acid and Myeloperoxidase

Osteopontin in Pulmonary Hypertension

Clinical and Molecular Implications of Osteopontin in Heart Failure

Contact Info

Product

Resources

About